

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
17 October 2024 (17.10.2024)



(10) International Publication Number  
**WO 2024/216048 A1**

(51) International Patent Classification:  
C07D 513/22 (2006.01) A61K 31/5025 (2006.01)  
A61P 35/00 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:  
PCT/US2024/024294

**Declarations under Rule 4.17:**  
— as to applicant's entitlement to apply for and be granted a  
patent (Rule 4.17(ii))

(22) International Filing Date:  
12 April 2024 (12.04.2024)

**Published:**  
— with international search report (Art. 21(3))

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
63/459,403 14 April 2023 (14.04.2023) US

(71) Applicant: **REVOLUTION MEDICINES, INC.**  
[US/US]; 700 Saginaw Drive, Redwood City, CA 94063  
(US).

(72) Inventors: **LI, Shaoling**; Revolution Medicines, Inc., 700  
Saginaw Drive, Redwood City, CA 94063 (US). **MAN-  
THATI, Suresh**; Revolution Medicines, Inc., 700 Saginaw  
Drive, Redwood City, CA 94063 (US). **CHOU, Kang-Jye**;  
Revolution Medicines, Inc., 700 Saginaw Drive, Redwood  
City, CA 94063 (US). **HUANG, Jun**; Revolution Medi-  
cines, Inc., 700 Saginaw Drive, Redwood City, CA 94063  
(US). **HUANG, Xiaojun**; Revolution Medicines, Inc., 700  
Saginaw Drive, Redwood City, CA 94063 (US).

(74) Agent: **BELLIVEAU, Michael, J.** et al.; Clark & Elbing  
LLP, 101 Federal Street, 15th Floor, Boston, MA 02110  
(US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,  
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,  
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,  
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,  
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, CV,  
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,  
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,  
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,  
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,  
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: CRYSTALLINE FORMS OF RAS INHIBITORS, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF  
USE THEREOF

(57) Abstract: The disclosure features crystalline forms of Ras inhibitors, pharmaceutical compositions thereof, and their uses in the  
treatment of cancers.

WO 2024/216048 A1